Publications by authors named "V Siozopoulou"
Background: It remains challenging to obtain positive outcomes with chimeric antigen receptor (CAR)-engineered cell therapies in solid malignancies, like colorectal cancer (CRC) and pancreatic ductal adenocarcinoma (PDAC). A major obstacle is the lack of targetable surface antigens that are not shared by healthy tissues. CD70 emerges as interesting target, due to its stringent expression pattern in healthy tissue and its apparent role in tumor progression in a considerable amount of malignancies.
View Article and Find Full Text PDFArticle Synopsis
- Testing for EGFR mutations is crucial for metastatic non-squamous non-small-cell lung cancer, but practical challenges like access to testing and limited tissue samples hinder routine biomarker testing in European labs.
- A validated online survey conducted among 64 expert labs revealed varying turnaround times and testing practices, with a significant portion only conducting EGFR testing upon clinician request.
- Despite these issues, testing rates remained stable during the COVID-19 pandemic, but overall there is significant variability in testing methods and quality assurance across different European laboratories.
Soft tissue and bone sarcomas are rare entities, hence, standardized therapeutic strategies are difficult to assess. Immunohistochemistry was performed on 68 sarcoma samples to assess the expression of PD-1, PD-L1, IDO and CD70 in different tumor compartments and molecular analysis was performed to assess microsatellite instability status. PD-1/PD-L1, IDO and CD70 pathways are at play in the immune evasion of sarcomas in general.
View Article and Find Full Text PDFNeutrophilic dermatoses and aneurysms: An overlooked association?
J Eur Acad Dermatol Venereol
December 2023